Stock NAVA NAVAMEDIC ASA
Add to a list
To use this feature you must be a member
Log inSign up

Financials Navamedic ASA

Equities

NAVA

NO0010205966

Pharmaceuticals

Market Closed - Oslo Bors
Other stock markets
 10:45:00 2024-04-26 am EDT 		5-day change 1st Jan Change
34 NOK -0.29% Intraday chart for Navamedic ASA -0.29% -7.36%
Mar. 13 Ingerø Reiten Investment Divests Navamedic Stake in NOK95 Million Deal MT
Mar. 12 An unknown buyer acquired unknown minority stake in Navamedic ASA (OB:NAVA) from Ingerø Reiten Investment Company As for NOK 95 million. CI

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024 2025
Capitalization 1 292.1 555.8 601.2 592.7 592.7 -
Enterprise Value (EV) 1 292.1 542.1 597.9 745.4 632.7 491.4
P/E ratio - 850 x 20.2 x 40.2 x 15 x 9.86 x
Yield - - - - - -
Capitalization / Revenue 1.39 x 2 x 1.57 x 1.24 x 0.97 x 0.85 x
EV / Revenue 1.39 x 1.95 x 1.56 x 1.46 x 1.04 x 0.71 x
EV / EBITDA - 29.8 x 11.6 x 14.5 x 8.96 x 5.03 x
EV / FCF - -267 x 38.1 x -7.28 x 45.2 x 16.4 x
FCF Yield - -0.37% 2.62% -13.7% 2.21% 6.1%
Price to Book - - 2.87 x 2.57 x 1.97 x 1.56 x
Nbr of stocks (in thousands) 15,292 16,346 17,228 17,433 17,433 -
Reference price 2 19.10 34.00 34.90 34.00 34.00 34.00
Announcement Date 4/30/21 2/17/22 2/16/23 2/15/24 - -
1NOK in Million2NOK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025
Net sales 1 209.9 278.4 382.1 512 608.7 695.9
EBITDA 1 - 18.2 51.69 51.57 70.64 97.76
EBIT 1 - 11.46 44.44 39.64 59.3 86.84
Operating Margin - 4.11% 11.63% 7.74% 9.74% 12.48%
Earnings before Tax (EBT) 1 - 2.358 42.51 10.83 51.9 80.22
Net income 1 - 0.618 29.43 3.814 40.8 63.02
Net margin - 0.22% 7.7% 0.74% 6.7% 9.06%
EPS 2 - 0.0400 1.730 0.8450 2.260 3.450
Free Cash Flow 1 - -2.028 15.69 -102.4 14 30
FCF margin - -0.73% 4.11% -20% 2.3% 4.31%
FCF Conversion (EBITDA) - - 30.36% - 19.82% 30.69%
FCF Conversion (Net income) - - 53.31% - 34.31% 47.6%
Dividend per Share 2 - - - - - -
Announcement Date 4/30/21 2/17/22 2/16/23 2/15/24 - -
1NOK in Million2NOK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2
Net sales 1 - 90.2 - 110.4 92.81 116 121.8 124 141 125.3 125.6 143
EBITDA 1 - 7.6 -0.4 23.71 12.67 15.72 15.82 10.5 17.4 7.912 8 14
EBIT 1 - 5.053 - 21.88 10.89 13.92 13.99 8.297 12.7 3.521 5.3 11
Operating Margin - 5.6% - 19.82% 11.74% 12% 11.49% 6.69% 9.01% 2.81% 4.22% 7.69%
Earnings before Tax (EBT) 1 - 1.979 - 9.575 5.244 27.16 - -17.08 10.22 0.119 4 8
Net income 1 -1.922 3.025 - 7.289 2.665 20.19 13.2 -15.77 6.772 -0.351 3 7
Net margin - 3.35% - 6.6% 2.87% 17.41% 10.84% -12.72% 4.8% -0.28% 2.39% 4.9%
EPS 2 - 0.1900 - 0.4300 - - - -0.9200 - 0.3100 0.1700 -
Dividend per Share - - - - - - - - - - - -
Announcement Date 11/4/21 2/17/22 5/12/22 8/12/22 11/1/22 2/16/23 5/11/23 8/11/23 11/1/23 2/15/24 - -
1NOK in Million2NOK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025
Net Debt 1 - - - 109 40 -
Net Cash position 1 - 13.6 3.3 - - 101
Leverage (Debt/EBITDA) - - - 2.104 x 0.5663 x -
Free Cash Flow 1 - -2.03 15.7 -102 14 30
ROE (net income / shareholders' equity) - 0.44% 12.7% 4.38% 16.4% 20.5%
ROA (Net income/ Total Assets) - - - - - -
Assets 1 - - - - - -
Book Value Per Share 2 - - 12.20 13.20 17.30 21.70
Cash Flow per Share - - - - - -
Capex 1 - 0.73 2.25 2.2 11 11
Capex / Sales - 0.26% 0.59% 0.43% 1.81% 1.58%
Announcement Date 4/30/21 2/17/22 2/16/23 2/15/24 - -
1NOK in Million2NOK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Navamedic ASA

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
34 NOK
Average target price
49 NOK
Spread / Average Target
+44.12%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
NAVAMEDIC ASA Stock Navamedic ASA
-7.36% 53.67M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. NAVA Stock
  4. Financials Navamedic ASA